Viyash Scientific: Business Overview & Financial Analysis
Viyash Scientific is an integrated pharmaceutical manufacturing and research enterprise headquartered in Hyderabad, Telangana. Promoted by Dr. Hari Babu and backed by private equity firm Carlyle Group, the company operates as an active pharmaceutical ingredient (API), intermediate, and custom synthesis partner. Managing automated chemical processing plants and R&D centers across Andhra Pradesh, Telangana, and Maharashtra, Viyash Scientific supplies key intermediates, chronic APIs, and contract development services to multinational generic pharmaceutical majors across regulated and emerging markets.
Product & Service Segment Breakdown of Viyash Scientific (FY2026)
Viyash Scientific structures its operational turnover across generic active pharmaceutical ingredients (APIs), advanced chemical intermediates, and custom synthesis services.
- Generic Active Pharmaceutical Ingredients (APIs) – 52.0% of Total Revenue
- Advanced Intermediates & Fine Chemicals – 32.5% of Total Revenue
- Custom Development & Manufacturing Services (CDMO) – 15.5% of Total Revenue
- Total Revenue from Operations (FY2026) – Rs 1,280.50 crore (+18.2% YoY)
Generic APIs serve as the primary top-line engine, focusing on high-barrier chronic therapeutic areas including anti-retroviral, oncology, and central nervous system care. Advanced chemical intermediates provide backward integration for global formulation makers, while CDMO contracts yield higher gross margins.
Therapeutic Segment Portfolio Share of Viyash Scientific (FY2026)
Viyash Scientific aligns its synthesis development around chronic and specialized sub-chronic therapeutic verticals.
- Anti-Retroviral (ARV) & Anti-Infective – 34.0% of Total Operating Revenue
- Central Nervous System (CNS) & Pain Care – 26.5% of Total Operating Revenue
- Oncology & High-Potency Molecules – 18.0% of Total Operating Revenue
- Cardiovascular & Anti-Diabetes – 14.5% of Total Operating Revenue
- Others & Specialty Intermediates – 7.0% of Total Operating Revenue
Anti-retroviral and CNS molecules anchor baseline volume dispatches across emerging and regulated markets. High-potency oncology APIs and cardiovascular intermediates expand unit realisations across North American and European generic accounts.
Geographic Revenue & Export Footprint of Viyash Scientific (FY2026)
Viyash Scientific balances direct domestic ingredient sales in India with expanding direct exports to international generic drug manufacturers.
- International Exports Contribution Share – 58.0% of Total Operating Revenue
- Domestic Indian Market Sales Share – 42.0% of Total Operating Revenue
- Regulated Markets Contribution Share – 68.0% of Total Export Sales (USA, Europe, Japan)
- Global Destination Footprint – Exports to 40+ countries across Americas, Europe, and Asia-Pacific
International exports generate nearly six-tenths of operational turnover, supported by USFDA and EU-GMP regulatory site approvals. Domestic sales supply integrated Indian formulation exporters and domestic pharmaceutical brands.
Manufacturing Facilities & Regulatory Status of Viyash Scientific (FY2026)
Viyash Scientific operates six production facilities equipped with multi-purpose chemical reactors and automated quality control testing suites.
- Operational Manufacturing Hubs – 6 plants in Visakhapatnam (Andhra Pradesh), Hyderabad (Telangana), and Raigad (Maharashtra)
- Total Group Installed Reactor Capacity – 1,200+ Kilo Litres (KL)
- Global Regulatory Site Approvals – USFDA, EDQM (Europe), WHO-GMP, and PMDA (Japan)
- Cumulative Regulatory Filings – 45+ US Drug Master Files (DMFs) and European CEPs
Manufacturing facilities in Visakhapatnam and Hyderabad process large-scale chemical synthesis and micronization. USFDA approvals across core manufacturing plants enable long-term commercial supply contracts with regulated market partners.
Latest Quarterly Financial Performance of Viyash Scientific (Q1 FY2027)
Viyash Scientific recorded top-line revenue expansion and operating profit growth during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 342.80 crore (+16.5% YoY)
- Consolidated Operating EBITDA – Rs 78.50 crore (+21.2% YoY)
- Operating EBITDA Margin – 22.90% (+89 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 48.20 crore (+25.4% YoY)
- CDMO Business Share – 18.2% of Quarterly Revenue
First-quarter operating revenue rose 16.5% year-on-year to Rs 342.80 crore, supported by higher CDMO project execution and export API dispatches. Consolidated Net Profit After Tax reached Rs 48.20 crore, while operating EBITDA margins expanded to 22.90%.
Consolidated Annual Financial Performance of Viyash Scientific (FY2026)
Viyash Scientific achieved record full-year operational turnover and net profitability for full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 1,280.50 crore (+18.2% YoY)
- Full Year Operating EBITDA – Rs 282.40 crore (+22.5% YoY)
- Full Year Operating EBITDA Margin – 22.05% (+78 bps YoY)
- Consolidated Net Profit After Tax (PAT) – Rs 172.50 crore (+26.8% YoY)
- Return on Capital Employed (ROCE) – 21.5%
Full-year operating turnover crossed Rs 1,280 crore in FY2026, as consolidated Net Profit After Tax expanded 26.8% to Rs 172.50 crore. Financial performance was driven by oncology API commercialization, capacity debottlenecking, and CDMO volume scaling.
Balance Sheet Structure & Financial Health Ratios of Viyash Scientific (Q1 FY2027)
Viyash Scientific maintains a disciplined capital structure supported by Carlyle Group equity backing and operational cash flow generation.
- Debt to Equity Ratio – Low Debt (0.18x)
- Total Cash, Bank Balances & Surplus Investments – Rs 320.00 crore
- Total Consolidated Net Worth Base – Rs 1,150.00 crore
- Return on Equity (ROE) – 18.2%
- Working Capital Cycle – 72 days
Total net worth expanded to Rs 1,150.00 crore as of June 30, 2026, with debt to equity holding low at 0.18x. Strong operational cash generation funds ongoing R&D and plant expansion projects without significant debt additions.
Capex Pipeline & Facility Expansion Roadmap of Viyash Scientific (FY2027–FY2028)
Viyash Scientific executes capital allocation outlays to construct a high-potency API (HPAPI) block and expand reactor capacities.
- Planned Multi-Year Capital Expenditure – Rs 200–250 crore over FY2027–FY2028
- Visakhapatnam Greenfield Expansion – Adding 300 KL reactor capacity for oncology intermediates
- High-Potency API (HPAPI) Block Outlay – Setting up specialized containment suites for potent active molecules
- R&D Center Modernization – Expanding flow chemistry and process analytical technology (PAT) labs in Hyderabad
- Funding Method – 80% funded through internal cash accruals and 20% bank line drawdowns
Annual capital expenditure is budgeted at Rs 200–250 crore to add 300 KL reactor capacity in Visakhapatnam and construct dedicated HPAPI containment suites. Internal cash flows fund the majority of modernizations to preserve balance sheet strength.
Management Commentary & Strategic Outlook of Viyash Scientific (Q1 FY2027)
Management guidance outlines strategic priorities centered on CDMO business expansion, HPAPI block commissioning, and regulated market share gains.
- Management targets achieving a 20%–22% revenue CAGR over the FY2027–FY2029 period.
- Operating EBITDA margins are guided to sustain within the 22.5%–24.0% corridor through high-margin CDMO execution.
- CDMO vertical share in overall revenue is targeted to expand toward 25% over the next 3 years.
- Regulatory DMF filings will prioritize complex oncology and central nervous system molecules in North America and Europe.
- Capital allocation strategy will maintain gearing below 0.30x while evaluating inorganic API asset acquisitions.
Management anticipates rising demand for supply-chain-diversified API manufacturing to drive custom synthesis and intermediate contracts. Operational focus centers on commissioning the Visakhapatnam HPAPI block, scaling flow chemistry R&D, and maintaining financial discipline.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Viyash Scientific Q1 FY2027 Consolidated Financial Disclosures (July/August 2026)
- Viyash Scientific Q4 & Full Year FY2026 Consolidated Financial Results Disclosures (May 2026)
- BSE Limited & National Stock Exchange of India (NSE) Corporate Filings for Viyash Scientific
- Ticker Finology Viyash Scientific Page
Disclaimer
The information presented above on Viyash Scientific has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Viyash Scientific page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.